首頁 > 市場調查報告書 > 醫療設備

體外診斷生技設備

市場調查報告書

商品編碼

1738547

2026 年至 2032 年免疫組織化學 (IHC) 市場（按產品、應用、最終用戶和地區分類）

Immunohistochemistry (IHC) Market By Product (Antibodies, Reagents), Application (Diagnostic, Research), End-User (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), & Region for 2026-2032

出版日期: 2025年05月12日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

免疫組織化學（IHC）市場評估 - 2026-2032

全球癌症患者數量的不斷成長推動了免疫組織化學 (IHC) 的應用。 IHC 技術的創新提高了其敏感度和特異性，吸引了更多研究人員和臨床醫生的注意。預計 2024 年 IHC 市場規模將超過 20.6 億美元，到 2032 年將達到約 33.7 億美元。

此外，政府對癌症研究的有利法規和資金支持也推動了免疫組織化學 (IHC) 的應用。個人化治療的轉變推動了對 IHC 精準生物標記的需求，預計這將推動市場在 2026 年至 2032 年期間以 6.37% 的複合年成長率成長。

免疫組織化學（IHC）市場：定義/概述

免疫組織化學 (IHC) 是一種實驗室技術，利用基於抗體的染色來觀察組織切片中特定蛋白質的存在和位置。此方法利用抗體與標靶抗原結合的特異性，使研究人員和臨床醫生能夠識別細胞結構並了解組織的病理變化。通常，組織會經過固定、切片，並用與可檢測標記物偶聯的抗體處理，以便在顯微鏡下進行觀察。

免疫組化 (IHC) 廣泛應用於臨床診斷和研究。在病理學中，它透過識別腫瘤標記和細胞分化，在診斷包括癌症在內的各種疾病中發揮著至關重要的作用。此外，IHC 也用於基礎研究，以研究蛋白質表現模式、細胞定位以及治療對特定細胞路徑的影響。它能夠為蛋白質表現提供空間背景，這對於理解疾病機制和組織結構至關重要。

VMR 內部

產業報告內容

我們的報告包含可操作的數據和前瞻性的分析，可協助您制定宣傳方案、建立商業計劃、組織簡報或撰寫提案。

個人化醫療領域不斷成長的研發活動將如何促進免疫組織化學 (IHC) 的採用？

全球癌症盛行率的上升是免疫組織化學 (IHC) 市場的主要驅動力。根據世界衛生組織 (WHO) 的數據，2020 年癌症將導致約 1000 萬人死亡，乳癌、肺癌、結腸癌和前列腺癌。 IHC 在癌症診斷、預後和治療計劃中發揮關鍵作用，因此對此類技術的需求不斷成長。多重 IHC 和數位病理學等 IHC 技術的最新進展進一步增強了 IHC 在腫瘤學中的效用。 2024 年 3 月，羅氏宣布推出一款全新的自動化 IHC 平台，旨在提高癌症診斷的工作流程效率和準確性。

個人化醫療領域活性化的研發投入正在推動免疫組化（IHC）市場的發展。美國國立衛生研究院 (NIH) 報告稱，將在 2023 財政年度撥款 4.19 億美元用於精準醫療研究。 IHC 技術對於識別特定的生物標記和分子標靶至關重要，從而能夠為個別患者制定個人化的治療策略。這一趨勢在針對各種疾病（包括自體免疫和神經退化性疾病）的標靶治療開發中尤為明顯。

新興經濟體對免疫組化（IHC）的日益普及正在推動市場成長。印度醫學研究理事會 (ICMR) 報告稱，2019 年至 2023 年期間，公立醫院的免疫組化檢測量將以每年 15% 的速度成長。推動這一趨勢的因素包括醫療基礎設施的改善、對先進診斷技術的認知不斷提高以及這些地區醫療支出的增加。免疫組化在診斷許多新興國家流行的感染疾病的多功能性，進一步推動了其應用。

不同平台和機構之間的標準化問題是否會阻礙市場成長？

不同平台和實驗室之間的標準化問題進一步加劇了IHC領域的複雜性。樣本製備、染色方案和解讀標準的差異可能導致結果不一致。標準化的缺乏會降低IHC觀察的可靠性，尤其是在需要一致性數據的多中心研究和臨床實驗室。

此外，分子技術和新一代定序等替代技術的出現，正在為IHC市場帶來競爭壓力。隨著這些替代技術變得更加先進和普及，它們可能為蛋白質分析和疾病表徵提供更可靠或更具成本效益的解決方案。隨著研究人員和臨床醫生不斷尋求新的診斷和研究方法，這種趨勢可能會限制IHC的發展和應用。

此外，監管環境對 IHC 市場也構成了挑戰：新抗體和診斷試劑套件的核准流程漫長而複雜，這可能會延遲創新產品的推出，嚴格的監管也會限制某些試劑的可用性，影響市場動態並為希望進入該領域的小公司設置障礙。

F. Agilent Technologies
Roche Diagnostics
Thermo Fisher Scientific
Merck KGaA
Abcam plc
Bio-Rad Laboratories
PerkinElmer, Inc.
Dako（part of Agilent）
Leica Biosystems
Cell Signaling Technology
F. Sigma-Aldrich（Merck）
Miltenyi BIoTec
Genetex, Inc.
Ventana Medical Systems（Roche）
Fujifilm
Biocare Medical
Santa Cruz BIoTechnology
Zymed Laboratories（Thermo Fisher）
NeoGenomics Laboratories
Enzo Life Sciences

第11章公司簡介附錄

相關調查

簡介目錄

Product Code: 60441

Immunohistochemistry (IHC) Market Valuation - 2026-2032

Increasing cancer cases globally is propelling the adoption of immunohistochemistry (IHC). Innovations in IHC techniques enhance sensitivity and specificity, attracting more researchers and clinicians is driving the market size surpass USD 2.06 Billion valued in 2024 to reach a valuation of around USD 3.37 Billion by 2032.

In addition to this, favorable government regulations and funding for cancer research is spurring up the adoption of immunohistochemistry (IHC). The shift towards tailored therapies boosts the need for precise biomarkers identified through IHC, this is enabling the market grow at a CAGR of 6.37% from 2026 to 2032.

Immunohistochemistry (IHC) Market: Definition/ Overview

Immunohistochemistry (IHC) is a laboratory technique used to visualize the presence and location of specific proteins in tissue sections using antibody-based staining. This method leverages the specificity of antibodies to bind to target antigens, allowing researchers and clinicians to identify cellular structures and understand pathological changes in tissues. Typically, tissues are fixed, sectioned, and treated with antibodies that are linked to a detectable marker, enabling visualization under a microscope.

IHC is widely utilized in both clinical diagnostics and research. In pathology, it plays a crucial role in diagnosing various diseases, including cancers, by identifying tumor markers and cellular differentiation. Additionally, IHC is used in basic research to study protein expression patterns, cellular localization, and the effects of treatments on specific cellular pathways. Its ability to provide spatial context to protein expression makes it invaluable in understanding disease mechanisms and tissue architecture.

What's inside a VMR

industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How will Rising Research and Development Activities in the Field of Personalized Medicine Increasing Adoption of Immunohistochemistry (IHC)?

The growing prevalence of cancer worldwide is a significant driver of the Immunohistochemistry (IHC) market. According to the World Health Organization, cancer was responsible for nearly 10 million deaths in 2020, with breast, lung, colon, and prostate cancers being the most common types. IHC plays a crucial role in cancer diagnosis, prognosis, and treatment planning, leading to increased demand for these techniques. Recent advancements in IHC technologies, such as multiplex IHC and digital pathology, have further enhanced its utility in oncology. In March 2024, Roche announced the launch of its new automated IHC platform, aiming to improve workflow efficiency and accuracy in cancer diagnostics.

Increasing research and development activities in the field of personalized medicine are propelling the IHC market forward. The U.S. National Institutes of Health (NIH) reported allocating $419 million for precision medicine research in the fiscal year 2023. IHC techniques are essential for identifying specific biomarkers and molecular targets, enabling tailored treatment strategies for individual patients. This trend is particularly evident in the development of targeted therapies for various diseases, including autoimmune disorders and neurodegenerative conditions.

The rising adoption of IHC in emerging economies is driving market growth. The Indian Council of Medical Research (ICMR) reported a 15% annual increase in IHC test volumes across public hospitals from 2019 to 2023. Factors contributing to this trend include improving healthcare infrastructure, increasing awareness about advanced diagnostic techniques, and growing healthcare expenditure in these regions. IHC's versatility in diagnosing infectious diseases, which are prevalent in many developing countries, further fuels its adoption.

Will Issues of Standardization across Different Platforms and Institutions Hindering the Market Growth?

The issue of standardization across different platforms and institutions further complicates the IHC landscape. Variability in sample preparation, staining protocols, and interpretation criteria can lead to discrepancies in results. This lack of standardization can undermine confidence in IHC findings, particularly in multicenter studies or clinical trials where consistent data is essential.

Also, the emergence of alternative technologies, such as molecular techniques and next-generation sequencing, presents competitive pressure on the IHC market. As these alternatives become more advanced and accessible, they may offer more reliable or cost-effective solutions for protein analysis and disease characterization. This trend could potentially limit the growth and application of IHC, as researchers and clinicians explore new methods for their diagnostic and research needs.

Additionally, the regulatory landscape poses challenges for the IHC market. The approval processes for new antibodies and diagnostic kits can be lengthy and complex, slowing down the introduction of innovative products. Stringent regulations can also limit the availability of certain reagents, affecting the market dynamics and creating barriers for smaller companies aiming to enter the field.

Category-Wise Acumens

Which Factors are Contributing Antibodies Segment Dominance in Immunohistochemistry (IHC) Market?

Antibodies are at the forefront of the Immunohistochemistry (IHC) market, playing a crucial role in detecting and visualizing specific antigens in tissue samples. Primary antibodies, in particular, are essential for precise target identification and are available in both monoclonal and polyclonal forms. According to the National Cancer Institute, over 80% of cancer diagnoses in the United States involved IHC techniques in 2023, highlighting the widespread use of antibodies in clinical settings. The continuous development of highly specific and sensitive antibodies has significantly improved the accuracy and reliability of IHC assays.

The demand for multiplex IHC antibodies is rapidly growing, driven by the need to analyze multiple biomarkers simultaneously in complex diseases like cancer. The U.S. Food and Drug Administration (FDA) approved 14 companion diagnostic IHC tests between 2020 and 2023, many of which utilize multiplex antibody panels. This trend reflects the increasing importance of comprehensive molecular profiling in personalized medicine. Multiplex IHC allows researchers and clinicians to gain deeper insights into cellular interactions and disease mechanisms, leading to more informed treatment decisions.

Which Factors Enhance the Use of Immunohistochemistry (IHC) for Diagnostics?

Diagnostics continue to dominate the Immunohistochemistry (IHC) market, with cancer diagnosis being a primary application. IHC techniques are crucial for identifying specific biomarkers, determining tumor origin, and guiding treatment decisions in oncology. According to the National Cancer Institute, approximately 1.9 million new cancer cases were diagnosed in the United States in 2023, emphasizing the ongoing need for accurate diagnostic tools. The ability of IHC to provide detailed information about protein expression and cellular localization makes it indispensable in modern pathology laboratories.

IHC diagnostics are increasingly being utilized in the field of infectious diseases, particularly for identifying pathogens that are difficult to culture or detect through other methods. The Centers for Disease Control and Prevention (CDC) reported that IHC was used in 15% of challenging infectious disease cases in 2023, up from 10% in 2020. This trend has been accelerated by recent global health events, highlighting the need for rapid and accurate diagnostic techniques. IHC's ability to detect viral antigens in tissue samples has proven especially valuable in diagnosing and studying emerging infectious diseases.

Country/Region-wise Acumens

Will Presence of Major IHC Market Players in North America Driving Immunohistochemistry (IHC) Market Growth?

North America maintains its dominant position in the immunohistochemistry (IHC) market, driven by advanced healthcare infrastructure and high adoption rates of cutting-edge diagnostic technologies. The region's leadership is bolstered by substantial investment in research and development, particularly in the fields of oncology and personalized medicine. According to the National Cancer Institute, cancer research funding in the United States reached $7.1 billion in fiscal year 2023, highlighting the country's commitment to advancing diagnostic and treatment capabilities. This investment directly translates to increased demand for sophisticated IHC techniques and products. In January 2024, Roche Diagnostics unveiled its next-generation IHC platform in the U.S. market, featuring enhanced automation and improved staining consistency for more accurate diagnoses.

The presence of major IHC market players and a robust regulatory framework contribute significantly to North America's market dominance. The U.S. Food and Drug Administration (FDA) approved 28 IHC-based companion diagnostic tests between 2020 and 2023, underscoring the region's leadership in translating research into clinical applications. These approvals facilitate the integration of IHC diagnostics into standard clinical practice, particularly in oncology. The region's large and aging population, coupled with high healthcare expenditure, further drives market growth. In March 2024, Leica Biosystems, a key player in the North American market, announced a strategic partnership with a leading artificial intelligence company to develop AI-powered IHC image analysis tools, aimed at improving diagnostic accuracy and efficiency.

Will Rising Prevalence Of Cancer Enhance Adoption of Immunohistochemistry (IHC) in Asia Pacific?

The Asia Pacific region is experiencing rapid growth in the Immunohistochemistry (IHC) market, driven by increasing healthcare expenditure, rising cancer incidence, and growing awareness of advanced diagnostic techniques. Countries like China, Japan, and India are at the forefront of this expansion, with significant investments in healthcare infrastructure and research capabilities. According to the National Health Commission of China, the country's healthcare spending reached 7.12 trillion yuan (approximately USD 1.1 Trillion) in 2023, representing a substantial increase from previous years. This investment is translating into improved access to advanced diagnostic tools, including IHC. In April 2024, Roche Diagnostics announced the opening of a new IHC reagent manufacturing facility in Shanghai, aiming to meet the growing regional demand and reduce delivery times for critical diagnostic products.

The rising prevalence of cancer in the Asia Pacific region is a key factor driving the adoption of IHC techniques. The Indian Council of Medical Research (ICMR) reported that new cancer cases in India are projected to increase by 12% by 2025, emphasizing the urgent need for accurate and efficient diagnostic methods. This trend is prompting healthcare providers across the region to invest in advanced IHC platforms and expand their diagnostic capabilities. The increasing focus on personalized medicine and targeted therapies is further fueling the demand for IHC-based biomarker testing. In March 2024, Danaher Corporation's Leica Biosystems division launched a new line of IHC antibodies specifically designed for prevalent cancer types in the Asia Pacific region, demonstrating the market's potential for tailored diagnostic solutions.

Competitive Landscape

The immunohistochemistry (IHC) market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the immunohistochemistry (IHC) market include:

Agilent Technologies
Roche Diagnostics
Thermo Fisher Scientific
Merck KGaA
Abcam plc
Bio-Rad Laboratories
PerkinElmer, Inc.
Dako (part of Agilent)
Leica Biosystems
Cell Signaling Technology
Sigma-Aldrich (Merck)
Miltenyi Biotec
Genetex, Inc.
Ventana Medical Systems (Roche)
Fujifilm
Biocare Medical
Santa Cruz Biotechnology
Zymed Laboratories (Thermo Fisher)
NeoGenomics Laboratories
Enzo Life Sciences

Latest Developments

In September 2023, Thermo Fisher Scientific launched a new line of advanced antibodies specifically designed for immunohistochemistry applications, enhancing sensitivity and specificity in cancer diagnostics.
In August 2023, Bio-Techne announced a collaboration with leading academic institutions to develop novel multiplex IHC techniques, enabling simultaneous detection of multiple biomarkers in tissue samples.

1 INTRODUCTION OF GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET, BY PRODUCT

5.1 Overview
5.2 Antibodies
5.3 Reagents
5.4 Equipment
5.5 Kits

6 GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET, BY APPLICATION

6.1 Overview
6.2 Diagnostic
6.3 Research
6.4 Forensic

7 GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET, BY END USER

7.1 Overview
7.2 Hospitals & Diagnostic Laboratories
7.3 Academic & Research Institutes
7.4 Others

8 GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL IMMUNOHISTOCHEMISTRY (IHC) MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 F. Agilent Technologies
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Roche Diagnostics
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Thermo Fisher Scientific
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Merck KGaA
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Abcam plc
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Bio-Rad Laboratories
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 PerkinElmer, Inc.
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Dako (part of Agilent)
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Leica Biosystems
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Cell Signaling Technology
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments
10.11 F. Sigma-Aldrich (Merck)
- 10.11.1 Overview
- 10.11.2 Financial Performance
- 10.11.3 Product Outlook
- 10.11.4 Key Developments
10.12 Miltenyi Biotec
- 10.12.1 Overview
- 10.12.2 Financial Performance
- 10.12.3 Product Outlook
- 10.12.4 Key Developments
10.13 Genetex, Inc.
- 10.13.1 Overview
- 10.13.2 Financial Performance
- 10.13.3 Product Outlook
- 10.13.4 Key Developments
10.14 Ventana Medical Systems (Roche)
- 10.14.1 Overview
- 10.14.2 Financial Performance
- 10.14.3 Product Outlook
- 10.14.4 Key Developments
10.15 Fujifilm
- 10.15.1 Overview
- 10.15.2 Financial Performance
- 10.15.3 Product Outlook
- 10.15.4 Key Developments
10.16 Biocare Medical
- 10.16.1 Overview
- 10.16.2 Financial Performance
- 10.16.3 Product Outlook
- 10.16.4 Key Developments
10.17 Santa Cruz Biotechnology
- 10.17.1 Overview
- 10.17.2 Financial Performance
- 10.17.3 Product Outlook
- 10.17.4 Key Developments
10.18 Zymed Laboratories (Thermo Fisher)
- 10.18.1 Overview
- 10.18.2 Financial Performance
- 10.18.3 Product Outlook
- 10.18.4 Key Developments
10.19 NeoGenomics Laboratories
- 10.19.1 Overview
- 10.19.2 Financial Performance
- 10.19.3 Product Outlook
- 10.19.4 Key Developments
10.20 Enzo Life Sciences
- 10.20.1 Overview
- 10.20.2 Financial Performance
- 10.20.3 Product Outlook
- 10.20.4 Key Developments